The Cerebral Infarction (Brain Infarction) drugs in development market research report provides comprehensive information on the therapeutics under development for Cerebral Infarction (Brain Infarction), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cerebral Infarction (Brain Infarction). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cerebral Infarction (Brain Infarction) and features dormant and discontinued products.

GlobalData tracks 12 drugs in development for Cerebral Infarction (Brain Infarction) by 12 companies/universities/institutes. The top development phase for Cerebral Infarction (Brain Infarction) is preclinical with seven drugs in that stage. The Cerebral Infarction (Brain Infarction) pipeline has eight drugs in development by companies and four by universities/ institutes. Some of the companies in the Cerebral Infarction (Brain Infarction) pipeline products market are: GNT Pharma, Okayama University and Beijing Tide Pharmaceutical.

The key targets in the Cerebral Infarction (Brain Infarction) pipeline products market include High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1), Free Radical, and Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B).

The key mechanisms of action in the Cerebral Infarction (Brain Infarction) pipeline product include Free Radical Scavenger with two drugs in Phase II. The Cerebral Infarction (Brain Infarction) pipeline products include four routes of administration with the top ROA being Intravenous and six key molecule types in the Cerebral Infarction (Brain Infarction) pipeline products market including Cell Therapy, and Small Molecule.

Cerebral Infarction (Brain Infarction) overview

Cerebral infarction results in an area of necrotic tissue in the brain (a cerebral infarct). It is caused by disrupted blood supply (ischemia) and restricted oxygen supply (hypoxia), most commonly due to thromboembolism, and manifests clinically as ischemic stroke. Major risk factors for cerebral infarction are generally the same as for atherosclerosis. These include high blood pressure, diabetes mellitus, tobacco smoking, obesity, and dyslipidemia.

For a complete picture of Cerebral Infarction (Brain Infarction)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.